Bio-Optronics Builds Oncology-Specific Features into CTMS
Bio-Optronics has built oncology-specific function into its CTMS, Clinical Conductor
Bio-Optronics has built oncology-specific function into its CTMS, Clinical Conductor. These features include adaptive and dynamic protocol design; billing compliance function that allows organizations managing and executing oncology studies to create multiple versions of cost-allocation grids for multi-arm trials, providing more accurate billing information with less time and effort; and financial tools to accommodate complex and changing protocols, allowing organizations to effectively bill for recurring visits and other complexities that result from oncology protocol design. In addition to this, organizations can set specific Medicare coverage designations at specific sites.Finally, the CTMS contains National Cancer Institute reporting functionality that creates NCI-compliant reports and allows researchers to adhere to NCI grant requirements more easily.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
